While our study demonstrated the efficacy of recombinant CXCR3-S2 peptide traps in reducing CNV and macrophage recruitment, Denoyer et al. showed that a small molecule CXCR3 antagonist in a rat model of ocular hypertension decreases intraocular pressure, prevents retinal neurodegeneration, and preserves visual function by restoring trabecular function [37]. Here, CXCR3 is linked to ocular hypertension.